

IDS/#2
J
10/26/01

I hereby certify that this paper is being deposited with the U.S. Postal Service "Express Mail Post Office to Addressee" in an envelope addressed to: Box PATENT APPLICATION, Assistant Commissioner for Patents, Washington, D.C. 20231 on July 25, 2001.

Carole J. Smith
Carole J. Smith

July 25, 2001
Date of Signature

1050 U.S. PTO
09/15/11
07/25/01

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of
Richard HORUK

Serial No. Not Yet Known

Filed Herewith

:
:
: Group Art Unit Not Yet Known
: Examiner Not Yet Known

Title: NON-PEPTIDE CCR1 RECEPTOR ANTAGONISTS IN COMBINATION WITH
CYCLOSPORIN A FOR THE TREATMENT OF HEART TRANSPLANT REJECTION

Box PATENT APPLICATION
Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR 1.97

In accordance with Applicants' duty of disclosure under 37 CFR 1.56(a), Applicants direct the attention of the Office to the following documents, which are listed on attached modified Form PTO-1449 (1 page). These documents may be material to the examination of the above-identified patent application filed herewith.

1. U.S. Patent No. 6,207,665 (Bauman *et al.*), which discloses acyl piperazine derivatives useful as anti-inflammatory agents.
2. Patent Cooperation Treaty Published Patent Application 00/44365 (Hancock), which discloses a method for inhibiting the rejection of transplanted grafts with an antagonist of CCR1 function.
3. Patent Cooperation Treaty Published Patent Application 00/16796 (Gröne *et al.*), which discloses use of a chemokine receptor antagonist together with a cyclosporin for treating or preventing transplant rejection.
4. Horuk, *et al.*, "A non-peptide functional antagonist of the CCR1 chemokine receptor is effective in rat heart transplant rejection", *J. Biol. Chem.*, (2001) 276(6):4199-4204.
5. Gröne *et al.*, "Met-RANTES reduces vascular and tubular damage during acute renal transplant rejection: blocking monocyte arrest and recruitment", *FASEB J.*, (1999) 13:1371:1383.
6. Liang *et al.*, "Species selectivity of a small molecule antagonist for the CCR1 chemokine receptor", *Eur. J. Phar.*, (2000) 389:41-49.

7. Liang *et al.*, "Identification and characterization of a potent, selective, and orally active antagonist of the CC chemokine receptor-1", *J. Biol Chem.*, (2000) 275(25):19000-19008.
8. Hesselgesser *et al.*, "Identification and characterization of small molecule functional antagonists of the CCR1 chemokine receptor", *J. Biol. Chem.*, (1998) 273(25):15687-15692.
9. Ng *et al.*, "Discovery of novel non-peptide CCR1 receptor antagonists", *J. Med. Chem.*, (1999) 42:4680-4694.
10. Gao *et al.*, "Targeting of the chemokine receptor CCR1 suppresses development of acute and chronic cardiac allograft rejection", *J. Clin. Invest.*, (2000) 105(1):35-44.
11. Horuk *et al.*, "CCR1 specific non-peptide antagonist: efficacy in a rabbit allograft rejection model", *Immunol Lett.* (2001) 76(3):193-201.

Copies of the above-listed documents are provided herewith.

Applicants make no admission by the citation of these documents that any of them necessarily constitute "prior art" to the instant application.

The Examiner is respectfully requested to consider these documents and to indicate that this has been done by initialing and returning a copy of the modified Form PTO-1449 filed herewith to the Applicants, in accordance with MPEP 609.

Respectfully submitted,

Wendy L. Washtien

Wendy L. Washtien, Ph.D.
Agent for Applicants
Registration No. 36,301

Berlex Biosciences
15049 San Pablo Avenue
P.O. Box 4099
Richmond, California 94804-0099
Tel: 510.262.5411
Fax: 510.262.7095
E-mail: wendy_washtien@berlex.com
Date: July 25, 2001

INFORMATION DISCLOSURE CITATION <small>(Use several sheets if necessary)</small>	ATTY. DOCKET NO. 51882AUSM1	SERIAL NO. Not Yet Known
	APPLICANT(S) Richard HORUK	
	FILING DATE Herewith	GROUP Not Yet Known

11050 U.S. PRO
 09/915411
 07/25/01

U.S. PATENT DOCUMENTS						
Initial		Document Number	Date	Name	Class/ Subclass	Filing Date
	01	6,207,665	3/2001	Bauman et al.		6/1998
FOREIGN PATENT DOCUMENTS						
Initial		Document Number	Date	Country	Translation	
					Yes	No
	02	WO00/44365	3/2000	PCT	X	
	03	WO00/16796	3/2000	PCT	X	
OTHER DOCUMENTS (Include Author, Title, Date, Pertinent Pages, etc.)						
	04	Horuk, <i>et al.</i> , "A Non-peptide Functional Antagonist of the CCR1 Chemokine Receptor Is Effective in Rat Heart Transplant Rejection", <i>J. Biol. Chem.</i> , (2001) 276(6):4199-4204				
	05	Gröne <i>et al.</i> , "Met-RANTES reduces vascular and tubular damage during acute renal transplant rejection: blocking monocyte arrest and recruitment", <i>FASEB J.</i> , (1999) 13:1371:1383				
	05	Liang <i>et al.</i> , "Species selectivity of a small molecule antagonist for the CCR1 chemokine receptor", <i>Eur. J. Phar.</i> , (2000) 389:41-49				
	07	Liang <i>et al.</i> , "Identification and Characterization of a Potent, Selective, and Orally Active Antagonist of the CC Chemokine Receptor-1", <i>J. Biol. Chem.</i> , (2000) 275(25):19000-19008				
	05	Hesseltgesser <i>et al.</i> , "Identification and Characterization of Small Molecule Functional antagonists of the CCR1 Chemokine Receptor", <i>J. Biol. Chem.</i> , (1998) 273(25):15687-15692				
	09	Ng <i>et al.</i> , "Discovery of Novel Non-Peptide CCR1 Receptor Antagonists", <i>J. Med. Chem.</i> , (1999) 42:4680-4694				
	10	Gao <i>et al.</i> , "Targeting of the chemokine receptor CCR1 suppresses development of acute and chronic cardiac allograft rejection", <i>J. Clin. Invest.</i> , (2000) 105(1):35-44				
	11	Horuk <i>et al.</i> , "CCR1 specific non-peptide antagonist: efficacy in a rabbit allograft rejection model", <i>Immunol. Lett.</i> (2001) 76(3):193-201				

EXAMINER	DATE CONSIDERED
<small>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</small>	